Brigid Makes Biography and Net Worth

Director of Elutia

Brigid Makes has served as a member of our board of directors since September 2020. Ms. Makes has served as an independent consultant for medical device and healthcare companies since July 2017, specifically advising on finance, accounting and funding responsibilities. From September 2011 to July 2017, Ms. Makes served as Senior Vice President and Chief Financial Officer of Miramar Labs, Inc., a biotechnology company focused on aesthetics and dermatology. From 2006 to 2011, Ms. Makes served as Senior Vice President and Chief Financial Officer of AGA Medical Corp, a medical device company developing interventional devices for the minimally invasive treatment of structural heart defects and peripheral vascular disorders. Prior to joining AGA, Ms. Makes held various positions at Nektar Therapeutics Inc. from 1999 to 2006, including serving as Chief Financial Officer. Since December 2019, Ms. Makes has also been a member of the board of directors of Mind Medicine (MindMed) Inc., a publicly traded neuro-pharmaceutical company, where Ms. Makes serves on the Audit Committee, the Compensation Committee and the Nominating/Governance Committee. Since June 2021, she also has served as a member of the board of directors and as chair of the Audit Committee for Quantum-Si, Inc, a life sciences tools company focused on commercializing a unique protein sequencing platform. Ms. Makes holds an M.B.A. from Bentley University and a Bachelor of Commerce degree in Finance & International Business from McGill University.

What is Brigid Makes' net worth?: The estimated net worth of Brigid Makes is at least $21.87 thousand as of December 17th, 2025. Makes owns 27,000 shares of Elutia stock worth more than $21,870 as of September 28th. This net worth estimate does not reflect any other assets that Makes may own. Learn More about Brigid Makes' net worth.
How do I contact Brigid Makes?: The corporate mailing address for Makes and other Elutia executives is 12510 Prosperity Drive, Suite 370, Silver Spring, MD, 20904. Elutia can also be reached via phone at (240) 247-1143 and via email at [email protected]. Learn More on Brigid Makes' contact information.
Has Brigid Makes been buying or selling shares of Elutia?: Brigid Makes has not been actively trading shares of Elutia during the past quarter. Most recently, on Wednesday, December 17th, Brigid Makes bought 25,000 shares of Elutia stock. The stock was acquired at an average cost of $0.52 per share, with a total value of $13,000.00. Following the completion of the transaction, the director now directly owns 27,000 shares of the company's stock, valued at $14,040. Learn More on Brigid Makes' trading history.
Who are Elutia's active insiders?: Elutia's insider roster includes Thomas Englese (Insider), Matthew Ferguson (CFO), Ronald Lloyd (CEO), Brigid Makes (Director), and Kevin Rakin (Director). Learn More on Elutia's active insiders.
Are insiders buying or selling shares of Elutia?: In the last year, Elutia insiders bought shares 13 times. They purchased a total of 299,500 shares worth more than $220,810.00. The most recent insider tranaction occured on January, 30th when Director Guido J Neels bought 20,000 shares worth more than $20,800.00. Insiders at Elutia own 17.8% of the company. Learn More about insider trades at Elutia.
Information on this page was last updated on 1/30/2026.

Brigid Makes Insider Trading History at Elutia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/17/2025	Buy	25,000	$0.52	$13,000.00	27,000
12/9/2022	Buy	2,000	$3.65	$7,300.00	2,000

Brigid Makes Buying and Selling Activity at Elutia

Elutia Company Overview

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators. The company also develops CanGarooRM, a combination of the CanGaroo envelope with antibiotics, to reduce the risk of infection after surgical implantation of an electronic device. In addition, it provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material to repair or reconstruct the peripheral vasculature. Further, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction surgeries following mastectomy. It serves hospitals and healthcare facilities through its direct sales force, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Today's Range

Now: $0.81

$0.81

$0.83

50 Day Range

MA: $0.87

$0.79

$1.01

2 Week Range

Now: $0.81

$0.50

$1.39

Volume

5,638 shs

Average Volume

135,291 shs

Market Capitalization

$35.87 million

P/E Ratio

0.85

Dividend Yield

N/A

Beta

0.88